Physios Biotech Inc. is a start-up company founded in 2023 to develop a novel MPS for customers, commercialize MPS, and provide drug evaluation services using MPS. We are engaged in the development of MPS that enable to predict human physiology and recapitulate human diseases.
One of founders, Prof. R. Yokokawa with Kyoto University, has established renal MPS containing highly functional proximal tubule cells from human iPS cells. This MPS makes it possible to evaluate renal drug transport, which was difficult to assess using conventional cultured cells. His group has also worked on evaluating novel therapeutics for rare cancers, reproducing the cancer microenvironment, and co-culturing with three-dimensional tissues using perfusable vascular networks in MPS. Based on these core technologies, we aim to contribute to reducing the usage of experimental animals, shortening of drug development times, and improving the safety assessment of compounds.
